Alice announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study of injectable AST1001 developed independently by the company to treat adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment was approved for drug clinical trials. This drug is a bispecific antibody conjugate drug targeting EGFR and c-Met. In October 2026, the drug was approved by the US FDA for phase I clinical research with the same indications. The approval of the clinical trial will not have a significant impact on the company's recent performance.

Alice announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study of injectable AST1001 developed independently by the company to treat adult patients with locally advanced or metastatic solid tumors who have previously failed standard treatment was approved for drug clinical trials. This drug is a bispecific antibody conjugate drug targeting EGFR and c-Met. In October 2026, the drug was approved by the US FDA for phase I clinical research with the same indications. The approval of the clinical trial will not have a significant impact on the company's recent performance.